Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis

Inflammation Research

Volumn 55, Issue 2, 2006, Pages 60-65

  Janusz, M J ^a   Hookfin, E B ^a   Brown, K K ^a   Hsieh, L C ^a   Heitmeyer, S A ^a   Taiwo, Y O ^a   Natchus, M G ^a   Pikul, S ^a   Almstead, N G ^a   De, B ^a   Peng, S X ^a   Baker, T R ^a   Patel, V ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Carboxylic acid; Hydroxamic acid; Matrix metalloproteinase inhibitors

Indexed keywords

IODOACETIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; PGE 2909492; PGE 3321996; PGE 6292544; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE DEGENERATION; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; OSTEOARTHRITIS; PLASMA PROTEIN BINDING; RAT; ULTRAFILTRATION;

AMINO ACIDS; ANIMALS; CARBOXYLIC ACIDS; CARTILAGE; DISEASE MODELS, ANIMAL; HUMANS; HYDROXAMIC ACIDS; IODOACETATES; KNEE JOINT; MALE; MATRIX METALLOPROTEINASES; MOLECULAR STRUCTURE; OSTEOARTHRITIS; PHENYLALANINE; PLASMA; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; SULFONES;

EID: 33645832556     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-005-0014-4     Document Type: Article

References (31)

1. Clark IM, Parker AE. Metalloproteinase: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 2003; 7: 19-34.
2. Gravallese EM., Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991; 34: 1074-84.
3. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1996; 36: 181-89.
4. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992; 35: 35-41.
5. Macachren SS. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum 1991; 34: 1085-93.
6. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA Rosner PJ et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996; 97: 761-68.
7. Moldovan F, Pelletier JM, Hambor J, Cloutier JM, Pelletier JM. Collagenase-3 (matrix metalloproteinase 13) is preferentially localized in the deep later of human arthritic cartilage in situ. In vitro mimicking effect by transforming growth factor β. Arthritis Rheum 1997; 40: 1653-61.
8. Wernicke D, Seyfert C, Hinzmann B, Gromnica-Ihle E. Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. J Rheumatol 1996; 23: 590-95.
9. Skiles JW, Gonnella NC, Jeng AY. The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001; 8: 425-74.
10. Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Stimpson SA et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995; 182: 449-57.
11. DiMartino M, Wolff C, High W, Stroup G, Hoffman S, Laydon J et al. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNFα processing. Inflamm Res 1997; 46: 211-15.
12. Lewis EJ, Bishop J, Bottomley KMK, Bradshaw D, Brewster M, Broadhurst MJ et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 1997; 121: 540-46.
13. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA et al. Moderation of the iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage 2001; 9: 751-60.
14. Natchus MG, Bookland RG, De B, Almstead NG, Pikul S, Janusz MJ et al. J Med Chem 2000; 43: 4948-63.
15. Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KMK. Ro-32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 1998; 1639-44.
16. Sabatini M, Lesur C, Thomas M, Chomel A, Anract P, de Nanteuil G et al. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis Rheum 2005; 171-80.
17. Chau T, Jolly G, Plym JM, McHugh M, Bortolon E, Wakefield J et al. Inhibition of articular cartilage degradation in dog and guinea pig models of osteoarthrtis by the stromelysin inhibitor BAY 12-9566 Arthritis Rheum 1998; 41(9S): S300.
18. Leff RL, Elias I, Ionescu M, Reiner A, Poole AR. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 2003; 30: 544-49.
19. Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO et al. Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem 1999; 42: 4547-62.
20. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases FEBS 1992; 296: 233-36.
21. Craig WA, Suh B. Protein binding and antimicrobial effects: Methods for the determination of protein binding. In Antibiotics in Laboratory Medicine; V Lorian Ed.; Williams and Wilkins 1991: 367-402.
22. Kalbhen DA, Blum U. Theroretisches Koncept und experimentelle bestatigung fur ein neues arthrose-modell am versuchstier. Arzneimittelforshung Drug Res 1977; 27: 527-31.
23. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis. A dose-response study of loss of mobility, morphology and biochemistry. Arthritis Rheum 1997; 40: 1670-79.
24. Peng SX, VonBargen EC, Bornes DM, Pikul S. Permeability of articular cartilage to matrix metalloproteinase inhibitors. Pharm Res 1998; 15: 1414-18.
25. Kragh-Hansen U, Chuang TG, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002; 25: 695-704.
26. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001; 103: 2303-09.
27. Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M et al. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors. J Med Chem 2003; 46: 3840-52.
28. Mitchell PG, Magna HA, Reeves LM,Lopresti-Morrow LL, Yocum SA, Rosner PJ et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996; 97: 761-8.
29. Newhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 2001; 107: 35-44.
30. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002; 169: 2643-47.
31. Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II et al. Susceptibility of stromelysin-1 deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998; 41: 110-21.